Research & Development
FDA approves first respiratory syncytial virus vaccine
Arexvy is the first respiratory syncytial virus (RSV) vaccine approved for use in the U.S. It is indicated for the prevention of lower respiratory tract disease caused by the virus in individuals 60 years of age and older.
May 3, 2023
BD nabs CE Mark for respiratory viral panel
The panel, a molecular diagnostic combination test for SARS-CoV-2, influenza A + B, and respiratory syncytial virus (RSV), uses a nasal swab or nasopharyngeal swab sample.
June 30, 2022
Seegene secures EU approval for SARS-CoV-2 assay
The clearance will allow Seegene to market the assay to small hospitals, local clinics, and public health centers for identification of COVID-19, influenza A and B, and respiratory syncytial virus (RSV).
June 28, 2022
CorDX obtains CE Mark for test for COVID-19, flu A/B, RSV
"As COVID-19 infection prevention measures relax globally, COVID and other viral infections are projected to rise," CorDx founder and CEO Jeff Yufeng Li said in a statement.
June 2, 2022
FDA OKs Labcorp's over-the-counter COVID-19, RSV, flu test
The Labcorp Seasonal Respiratory Virus RT-PCR DTC (real time-polymerase chain reaction direct-to-consumer) test can detect and differentiate between the three respiratory viruses. It is authorized for at-home sample collection with testing performed in a lab. Results are delivered through an online portal, with follow-up from a healthcare provider for positive results.
May 15, 2022
Eurofins debuts 2 combined tests for COVID/influenza, RSV
The new multiplex kits have been granted the CE Mark and are designed to detect and differentiate three viral infections in the same PCR run, Eurofins said.
November 30, 2021
PerkinElmer receives EUA for respiratory SARS-CoV-2 panel
Qualified laboratories can immediately begin using the RT-PCR test for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) isolated from nasopharyngeal swabs, anterior nasal swabs, and midturbinate swabs, the company said.
October 6, 2021
Qiagen secures EUA for COVID-19 test
NeuMoDx Flu A-B/ respiratory syncytial virus (RSV)/SARS-CoV-2 Vantage is a polymerase chain reaction (PCR) assay that will enable clinicians to identify the cause of respiratory viral infection, whether it's due to SARS-CoV-2, influenza, or RSV.
March 28, 2021
Abbott gets EUA for COVID-19, flu, RSV assay
The test only requires one swab (anterior nasal or nasopharyngeal) collected by a healthcare provider or an anterior nasal swab specimen that is self-collected at a healthcare location. The assay runs on Abbott's high-volume Alinity m system, which uses polymerase chain reaction (PCR) technology.
March 4, 2021
Thermo Fisher completes Mesa Biotech acquisition
Mesa Biotech is known for its Accula system, a point-of-care polymerase chain reaction (PCR)-based testing platform for infectious disease diagnosis. Besides COVID-19, Accula also tests for influenza, respiratory syncytial virus (RSV), and group A Streptococcus.
February 25, 2021
GeneIQ debuts a SARS-CoV-2, RSV, influenza A/B test
The four-in-one test is available for symptomatic individuals. Patients are tested using nasal swabs, and the result turnaround time is about 24 hours.
January 5, 2021
Bruker launches panel for COVID-19, flu, RSV
The panel has been validated for nasopharyngeal swabs, oropharyngeal swabs, and saliva samples. The kit includes all reagents to generate up to 96 PCR result panels in less than two hours after nucleic acid extraction, the company said.
December 17, 2020
Page 1 of 2